{"id":"https://openalex.org/W2016561240","doi":"https://doi.org/10.1016/j.critrevonc.2015.03.011","title":"Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature","display_name":"Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature","alternate_titles":[],"publication_year":2015,"publication_date":"2015-04-27","ids":{"openalex":"https://openalex.org/W2016561240","doi":"https://doi.org/10.1016/j.critrevonc.2015.03.011","mag":"2016561240","pmid":"https://pubmed.ncbi.nlm.nih.gov/25964164"},"language":"en","primary_location":{"id":"doi:10.1016/j.critrevonc.2015.03.011","doi":"https://doi.org/10.1016/j.critrevonc.2015.03.011","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.critrevonc.2015.03.011","pdf_url":null,"source":{"id":"https://openalex.org/S185233701","display_name":"Critical Reviews in Oncology/Hematology","issn_l":"1040-8428","issn":["1040-8428","1879-0461"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Critical Reviews in Oncology/Hematology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2016561240"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091882595","display_name":"Pier Luigi Zinzani","orcid":"https://orcid.org/0000-0002-2112-2651","observed_orcids":["https://orcid.org/0000-0002-2112-2651"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"P.L. Zinzani","raw_affiliation_strings":["Institute of Haematology and Medical Oncology, 'L. & A. Ser\u00e0gnoli', University of Bologna, Bologna, Italy. Electronic address: pierluigi.zinzani@unibo.it","Institute of Haematology and Medical Oncology, L. & A. Ser\u00e0gnoli, University of Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Haematology and Medical Oncology, 'L. & A. Ser\u00e0gnoli', University of Bologna, Bologna, Italy. Electronic address: pierluigi.zinzani@unibo.it","institution_ids":["https://openalex.org/I9360294"]},{"raw_affiliation_string":"Institute of Haematology and Medical Oncology, L. & A. Ser\u00e0gnoli, University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059416243","display_name":"Stephanie Sasse","orcid":"https://orcid.org/0000-0002-1080-4606","observed_orcids":["https://orcid.org/0000-0002-1080-4606"]},"institutions":[{"id":"https://openalex.org/I4210153755","display_name":"University Hospital Cologne","ror":"https://ror.org/05mxhda18","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210153755"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Sasse","raw_affiliation_strings":["University Hospital of Cologne, Cologne, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital of Cologne, Cologne, Germany","institution_ids":["https://openalex.org/I4210153755"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011398209","display_name":"John A. Radford","orcid":"https://orcid.org/0000-0001-7898-2786","observed_orcids":["https://orcid.org/0000-0001-7898-2786"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Radford","raw_affiliation_strings":["The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK","institution_ids":["https://openalex.org/I28407311","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016826271","display_name":"Oluwatoyin O. Shonukan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"O. Shonukan","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108417203","display_name":"Vijayveer Bonthapally","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"V. Bonthapally","raw_affiliation_strings":["Global Outcomes and Epidemiology Research (GOER), Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Outcomes and Epidemiology Research (GOER), Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5091882595"],"corresponding_institution_ids":["https://openalex.org/I9360294"],"apc_list":{"value":4190,"currency":"USD","value_usd":4190},"apc_paid":null,"fwci":0.9712,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.67592593,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"95","issue":"3","first_page":"359","last_page":"369"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":1.0},{"id":"https://openalex.org/keywords/relapsed-refractory-hodgkin-lymphoma","display_name":"relapsed/refractory Hodgkin lymphoma","score":0.9929999709129333},{"id":"https://openalex.org/keywords/systemic-anaplastic-large-cell-lymphoma","display_name":"systemic anaplastic large cell lymphoma","score":0.968999981880188},{"id":"https://openalex.org/keywords/cd30","display_name":"CD30","score":0.6759999990463257},{"id":"https://openalex.org/keywords/named-patient-program","display_name":"named patient program","score":0.8500000238418579},{"id":"https://openalex.org/keywords/real-world-efficacy","display_name":"real-world efficacy","score":0.7210000157356262},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5789999961853027},{"id":"https://openalex.org/keywords/neurologic-toxicity","display_name":"neurologic toxicity","score":0.8379999995231628},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.9819999933242798},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.6159999966621399},{"id":"https://openalex.org/keywords/pooled-analysis","display_name":"pooled analysis","score":0.44699999690055847}],"concepts":[{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.9882931113243103},{"id":"https://openalex.org/C2777872185","wikidata":"https://www.wikidata.org/wiki/Q486090","display_name":"Anaplastic large-cell lymphoma","level":3,"score":0.834191083908081},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7750396728515625},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6936681270599365},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6728307008743286},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6306518316268921},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.608925461769104},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5807214975357056},{"id":"https://openalex.org/C70905583","wikidata":"https://www.wikidata.org/wiki/Q3648608","display_name":"CD30","level":3,"score":0.5658852458000183},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.26189371943473816},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000079963","descriptor_name":"Brentuximab Vedotin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017728","descriptor_name":"Lymphoma, Large-Cell, Anaplastic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1016/j.critrevonc.2015.03.011","doi":"https://doi.org/10.1016/j.critrevonc.2015.03.011","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.critrevonc.2015.03.011","pdf_url":null,"source":{"id":"https://openalex.org/S185233701","display_name":"Critical Reviews in Oncology/Hematology","issn_l":"1040-8428","issn":["1040-8428","1879-0461"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Critical Reviews in Oncology/Hematology","raw_type":"journal-article"},{"id":"pmid:25964164","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25964164","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Critical reviews in oncology/hematology","raw_type":"Journal Article"},{"id":"pmh:oai:USBKOELN.ub.uni-koeln.de:39531","doi":null,"is_oa":false,"landing_page_url":"https://kups.ub.uni-koeln.de/39531/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400371","display_name":"K\u00f6lner Universit\u00e4ts PublikationsServer (Universit\u00e4t zu K\u00f6ln)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210115942","host_organization_name":"Rhenish Institute for Environmental Research","host_organization_lineage":["https://openalex.org/I4210115942"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"doc-type:article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/be201674-cd75-4aa9-aa28-ceecacf0a80e","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/be201674-cd75-4aa9-aa28-ceecacf0a80e","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Zinzani, P L, Sasse, S, Radford, J, Shonukan, O & Bonthapally, V 2015, 'Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program : Review of the literature', Critical Reviews in Oncology/Hematology, vol. 95, no. 3, pp. 359-369. https://doi.org/10.1016/j.critrevonc.2015.03.011","raw_type":"info:eu-repo/semantics/review"},{"id":"pmh:oai:cris.unibo.it:11585/506371","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/11585/506371","pdf_url":null,"source":{"id":"https://openalex.org/S4306402579","display_name":"Archivio istituzionale della ricerca (Alma Mater Studiorum Universit\u00e0 di Bologna)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210117483","host_organization_name":"Istituto di Ematologia di Bologna","host_organization_lineage":["https://openalex.org/I4210117483"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1971264873","https://openalex.org/W2014213739","https://openalex.org/W2015397586","https://openalex.org/W2056942759","https://openalex.org/W2075217590","https://openalex.org/W2090057677","https://openalex.org/W2112271707","https://openalex.org/W2114005457","https://openalex.org/W2118805549","https://openalex.org/W2133201432","https://openalex.org/W2138352319","https://openalex.org/W2139891818","https://openalex.org/W2140902687","https://openalex.org/W2141354859","https://openalex.org/W2149997323","https://openalex.org/W2155256323","https://openalex.org/W2156506990","https://openalex.org/W2162417686","https://openalex.org/W2531692762","https://openalex.org/W2580422054","https://openalex.org/W2595722197"],"related_works":["https://openalex.org/W2397619099","https://openalex.org/W2050305366","https://openalex.org/W2887518486","https://openalex.org/W142061019","https://openalex.org/W1985984158","https://openalex.org/W2093699920","https://openalex.org/W2114680996","https://openalex.org/W6977008093","https://openalex.org/W2126879510","https://openalex.org/W2145174107"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2016561240","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
